Alternative Data for Opthea
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 21 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Employee Rating | 60 | Sign up | Sign up | Sign up |
| Reddit Mentions | 11 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 227 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Business Outlook | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 18 | Sign up | Sign up | Sign up |
About Opthea
Opthea Limited, a biotechnology company, develops and markets therapies primarily for eye diseases in Australia. The company is headquartered in South Yarra, Australia.
| Price | $3.41 |
| Target Price | Sign up |
| Market Cap | $525M |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Opthea (OPT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, reddit mentions, stocktwits mentions, stocktwits subscribers, news mentions, business outlook & linkedin employees.
FAQ - Opthea
The Market Cap of Opthea is $525M.
Currently, the price of one share of Opthea stock is $3.41.
The OPT stock price chart above provides a comprehensive visual representation of Opthea's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Opthea shares. Our platform offers an up-to-date OPT stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Opthea (OPT) does not offer dividends to its shareholders. Investors interested in Opthea should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Opthea are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
